MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.93
+0.70
+3.84%
Closed 16:20 11/15 EST
OPEN
18.35
PREV CLOSE
18.23
HIGH
19.19
LOW
18.30
VOLUME
684.32K
TURNOVER
--
52 WEEK HIGH
50.10
52 WEEK LOW
17.51
MARKET CAP
876.87M
P/E (TTM)
-4.3768
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AERI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AERI News

  • Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
  • Business Wire.5d ago
  • Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.6d ago
  • Why Aerie Pharmaceuticals Crashed 22.4% Today
  • MotleyFool.com.11/07 23:29
  • Piper Jaffray Maintains Overweight on Aerie Pharmaceuticals, Lowers Price Target to $48
  • Benzinga.11/07 17:04

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About AERI

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
More

Webull offers Aerie Pharmaceuticals Inc (AERI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.